Light Horse Therapeutics Inc.

Based in California, US, Light Horse Therapeutics Inc. operates as a biotechnology research company that develops gene editing platforms essential for drug discovery, primarily in the field of oncology. The firm was cofounded in 2020 by Brian Liau, Ben Cravatt, and Nathaniel Gray. In January 2025, Light Horse Therapeutics Inc.

raised USD 62 million in series A funding led by investor Versant Ventures, with participation from other investors Bristol-Myers Squibb Company, Taiho Ventures, AbbVie Biotech Ventures, and Mubadala Capital. The firm as of Jnauary 2025, is led by its Chairman of the board, Tom Daniel, and CEO, Markus Renschler. The company's core product offerings focus on identifying cryptic, chemically accessible functional domains within protein targets that contribute to the progression of disabling and life-threatening diseases. This advanced platform systematically analyzes complex signaling pathways, particularly in oncology, to uncover novel therapeutic targets.

By interrogating these targets within their native cellular context, Light Horse ensures that laboratory discoveries are effectively translated into clinical applications.   Light Horse Therapeutics operates on a revenue model encompassing strategic partnerships and collaborations with major pharmaceutical companies. The company plans to utilize the January 2025 funding to advance its preclinical programs in oncology, expand its proprietary drug discovery platform, and support ongoing collaborations.